Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

BFH772

Home DrugsBFH772

Investigational

Small Molecule

BFH772

Unknown Manufacturer

BFH772 is under investigation in clinical trial NCT01449591 (Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients).

Generate AI report

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Overview

BFH772 is under investigation in clinical trial NCT01449591 (Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients).

Technical identifiers

Chemical Formula: C₂₃H₁₆F₃N₃O₃
CAS Number: 890128-81-1
UNII ID: T1IV236CVP

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

WWP2 ubiquitinated BAF170 protein and pharmaceutical application thereof
Applicant: FIRST HOSPITAL CHINA MEDICAL UNIVPriority: 2025
CN
Application of compound for regulating and controlling BAF170 protein in preparation of medicine for preventing, relieving and/or treating cardiovascular diseases
Applicant: FIRST HOSPITAL CHINA MEDICAL UNIVPriority: 2025
CN